Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 64,223	$ 63,868	$ 191,622	$ 174,607
Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	59,058	57,902	181,368	158,849
Finished Pharmaceutical Products | Enoxaparin
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	15,363	21,264	51,049	64,647
Finished Pharmaceutical Products | Naloxone
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	12,407	10,519	38,222	27,944
Finished Pharmaceutical Products | Phytonadione
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	8,667	5,935	23,555	10,301
Finished Pharmaceutical Products | Epinephrine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	5,303	5,032	14,921	9,958
Finished Pharmaceutical Products | Lidocaine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	8,279	6,176	26,378	20,662
Finished Pharmaceutical Products | Other Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 9,039	$ 8,976	$ 27,243	$ 25,337